Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AdAPT-001 + unspecified immune checkpoint inhibitor |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AdAPT-001 | AdAPT 001|AdAPT001 | AdAPT-001 is an oncolytic adenovirus engineered to express a fusion protein composed of soluble TGFBR2 and the Fc region of IgG1, which binds to and sequesters TGFbeta, potentially inhibiting downstream signaling and tumor growth (PMID: 35950603). | ||
unspecified immune checkpoint inhibitor | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04673942 | Phase II | AdAPT-001 + unspecified immune checkpoint inhibitor AdAPT-001 | A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors (BETA-PRIME) | Recruiting | USA | 0 |